Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on October 1, 2018, regarding Pavmed Inc., a Delaware corporation. The filing primarily documents the results of the Company's annual meeting of shareholders held on that date. Pavmed Inc. is identified as an emerging growth company.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Corporate Actions
Shareholders approved four significant proposals at the annual meeting:
- Director Elections: James L. Cox, M.D., and David Weild IV were re-elected as Class B directors for a three-year term.
- Capital Structure Amendment: The Company's authorized common stock was increased by 25,000,000 shares, raising the total from 50,000,000 to 75,000,000 shares.
- Equity Plan Amendment: The 2014 Long-Term Incentive Equity Plan was amended to increase the number of shares available for grant by 3,000,000, raising the total from 2,951,081 to 5,951,081 shares.
- Auditor Ratification: Citrin Cooperman & Company, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
Voting Results and Management Commentary
The filing details the voting outcomes for each proposal:
| Proposal | For | Against | Abstain / Withheld |
|---|---|---|---|
| Election of Class B Directors | ~10.3M - 10.4M (per nominee) | N/A (Authority Withheld) | ~82K - 185K (per nominee) |
| Amendment to Certificate of Incorporation | 15,921,132 | 4,079,241 | 187,329 |
| Amendment to Equity Plan | 9,345,018 | 1,051,721 | 86,288 |
| Ratification of Auditor | 18,014,664 | 498,377 | 1,674,661 |
Management commentary is limited to the procedural confirmation that the amendments became effective upon filing with the State of Delaware on October 1, 2018. No specific risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the impact of the increased authorized share count (75M) on potential future dilution.
- Review the full text of the Second Amended and Restated 2014 Long-Term Incentive Equity Plan (Exhibit 10.1) to understand grant terms.
- Confirm the terms of the Certificate of Amendment to the Certificate of Incorporation (Exhibit 3.1).
- Check subsequent filings (e.g., 10-K or 10-Q) for the actual financial performance of the company, as this 8-K contains no financial data.